Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Suven Life Sciences Limited
SUVEN | NSE
147.43
INR15.73
11.94%
SUVEN | NSE
Loading StockChartView...
About Suven Life Sciences Limited
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
31/03/2024
As of date
01/04/2026
Close
147.43
Open
139.50
High
148.95
Low
135.50
Suven Life Sciences Limited a clinical-stage biopharmaceutical company focuses on the acquisition development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India the United States Europe and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031 a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911 a novel potent and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010 a potent selective and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
View LessSUVEN | NSE
Risk
64.8
Sharpe
0.24
Luna's Score
46/100
Recommendation
Hold
Luna says (SUVEN | NSE)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
80.5%1 month
64.8%3 months
60.3%6 months
48.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
10.70
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-11.71
Ent. to rev.
314.23
PEG
-
Other Fundamentals
EBITDA
-1.31B
MarketCap
32.58B
MarketCap(USD)
349.61M
Div. yield
-
Op. margin
-3.18K
Erngs. growth
1.56K
Rev. growth
-73.50
Ret. on equity
-32.56
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
24.84
Range1M
24.84
Range3M
54.39
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.83
Price X volume
134.96M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.71 | 24.85 | Cheaper |
| Ent. to Revenue | 314.23 | 11.40 | Expensive |
| PE Ratio | - | 51.36 | - |
| Price to Book | 10.70 | 6.83 | Expensive |
| Dividend Yield | - | 0.52 | - |
| Std. Deviation (3M) | 60.25 | 42.17 | Riskier |
| Debt to Equity | 0.00 | 0.35 | Cheaper |
| Debt to Assets | 0.00 | 0.17 | Cheaper |
| Market Cap | 32.58B | 290.82B | Emerging |
